Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jack Chapman

Interventional Pain Medicine New Braunfels, TX Medical Doctor

NPI 1710975701 CMS profile 214087

717 Generations Dr Ste B, New Braunfels, TX 78130

Open in the dashboard

General payments

$23,787

541 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jack Chapman of New Braunfels, TX is reported in the CMS Open Payments database as having received $23,787 across 541 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,813 72
2024 General $4,245 121
2023 General $4,064 108
2022 General $3,163 61
2021 General $1,588 57
2020 General $724 48
2019 General $2,191 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jack Chapman
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Jack Chapman were reported at $7,813. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Jack Chapman Interventional Pain Medicine median Middle half National median
2019 $2,191 $684 $216–$2,079 $163
2020 $724 $382 $122–$1,109 $114
2021 $1,588 $552 $167–$1,554 $132
2022 $3,163 $605 $187–$1,924 $149
2023 $4,064 $671 $195–$1,915 $160
2024 $4,245 $684 $206–$1,837 $164
2025 $7,813 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $7,177 330 payments
  2. SI-BONE, Inc. $6,377 32 payments
  3. Medtronic, Inc. $2,631 42 payments
  4. Painteq LLC $2,194 52 payments
  5. Boston Scientific Corporation $1,272 10 payments
  6. Medtronic USA, Inc. $1,096 17 payments
  7. SPR Therapeutics, Inc $710 11 payments
  8. MML US, Inc. $475 9 payments
  9. Nevro Corp. $332 7 payments
  10. Relievant Medsystems, Inc. $298 4 payments
  11. Other $1,225 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,777 521 payments
  2. Consulting Fee $5,500 6 payments
  3. Travel and Lodging $3,083 12 payments
  4. Education $427 2 payments
Products named General payments · program years 2019–2025
  1. IFUSE IMPLANT SYSTEM $5,500 6 payments
  2. PAINTEQ $2,194 52 payments
  3. PROCLAIM Neuromodulation $2,010 99 payments
  4. SYNCHROMEDII $1,638 19 payments
  5. OCTRODE $836 18 payments
  6. INTELLIS $830 5 payments
  7. PROCLAIM Neuromodulation $829 26 payments
  8. Proclaim IPG $821 38 payments
  9. Proclaim Family of SCS IPGs $729 22 payments
  10. SPRINT PNS System $710 11 payments
  11. Other $6,186 224 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

3,656

Median for Pain Management: 951

Drug cost

$121,354

Median for Pain Management: $26,034

Branded share of claims

57.8%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,517 $51,452
Xtampza Er Oxycodone Myristate Brand 20 $13,262
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 327 $12,246
Fentanyl Generic 106 $11,229
Morphine Sulfate Er Morphine Sulfate Brand 132 $4,308
Oxycodone Hcl Generic 191 $4,103
Gabapentin Generic 167 $3,588
Hydrocodone-Ibuprofen Hydrocodone/Ibuprofen Brand 12 $3,153
Hydromorphone Hcl Generic 186 $2,975
Tramadol Hcl Generic 204 $2,095

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$228,875

Of which drugs: $7,201

Medicare patients

319

Average age 74

Services billed

7,681

202 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 38%
Depression 38%
Diabetes 29%
Chronic kidney disease 29%
Atrial fibrillation 21%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 68 3,504 $362
Injection, methylprednisolone acetate, 40 mg J1030 Office 37 41 $161
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 34 148 $117
Injection, methylprednisolone acetate, 20 mg J1020 Office 23 25 $94
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 31 340 $31
Injection, ketorolac tromethamine, per 15 mg J1885 Office 21 80 $30

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $79
$79 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $16
$16 20 —
Tirosint
  • IBSA Pharma Inc. $6
$6 — —
Licart
  • IBSA Pharma Inc. $6
$6 — —
Flector
  • IBSA Pharma Inc. $6
$6 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

541 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record